Fluorescent nivolumab before surgery for head and neck cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests a new way to give an immunotherapy drug called nivolumab before surgery for head and neck cancer. The drug is injected directly into the tumor and is labeled with a fluorescent marker so researchers can see how it works in the removed tissue. This might help improve treatment for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with head and neck squamous cell carcinoma.
- Your treatment plan includes surgery to remove the cancer.
- You are at least 18 years old.
- You are generally healthy enough for surgery and anesthesia.
- You do not have certain autoimmune diseases or conditions that weaken your immune system (with some exceptions like well-controlled thyroid problems or type 1 diabetes).
- You are not planning to become pregnant or breastfeeding during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests if a special dye attached to the immunotherapy drug nivolumab can help surgeons see tumor cells during surgery for high grade glioma. You may join if you are scheduled for surgery and your organs are working well.
This trial tests whether giving nivolumab (an immunotherapy drug) before surgery helps treat oral squamous cell carcinoma (a type of mouth cancer). Nivolumab helps your immune system fight cancer cells.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.